

IN VITRO CYTOTOXIC ACTIVITY OF PHENANTHROLINE-BRIDGED DINUCLEAR PLATINUM(II) COMPLEXES

<u>Živković M.D.</u>, a Rajković S., b Franich A.A., b Zarić M., c Čanović P., c Marković N., d Djuran M.I. e

^a University of Kragujevac, Faculty of Medical Sciences, Department of Pharmacy, 34000 Kragujevac, Serbia, e-mail: mzivkovic@kg.ac.rs

b University of Kragujevac, Faculty of Science, Department of Chemistry, 34000 Kragujevac, Serbia
c University of Kragujevac, Faculty of Medical Sciences, Department of Biochemistry, 34000 Kragujevac, Serbia
d University of Kragujevac, Faculty of Medical Sciences, Department of Surgery, 34000 Kragujevac, Serbia
e Serbian Academy of Sciences and Arts, Knez Mihailova 35, Belgrade, Serbia

Platinum-based drugs is considered as the fundamental component of standard chemotherapy. Polynuclear Pt(II) complexes with aromatic nitrogen-containing heterocyclic bridging ligands represent a novel class of promising antitumor agents.1 In the present study, two dinuclear Pt(II) complexes, $[{Pt(en)Cl}_2(\mu-1,7-phen)](ClO_4)_2 \cdot H_2O$ (Pt1) and $[{Pt(en)Cl}_2(\mu-4,7-phen)](ClO_4)_2 \cdot H_2O$ (Pt2), have been synthesized and structurally characterized by elemental microanalyses, ¹H NMR, IR and UV-Vis spectroscopy.

In vitro cytotoxic activity of Pt1 and Pt2 complexes was evaluated against two tumor cell lines, the metastatic breast cancer (MDA-MB-231) and murine mammary carcinoma (4T1), and one normal human lung fibroblast cell (MRC-5). The results of the MTT assay indicate that complex Pt1 has a much lower IC50 value for activity on both cells compared with cisplatin. In comparison with cisplatin, these complexes showed lower cytotoxicity toward normal MRC-5 cell.

References

1. Senerović L., Živković M.D., Veselinović A., Pavić A., Djuran M.I., Rajković S., Nikodinovic-Runic J. J. Med. Chem. 2015, 58, 1442.

Financial support by the Ministry of Education, Science and Technological Development of the Republic of Serbia (Project No. 172036 and 175069) is gratefully acknowledged.